Comparing ethanol lock therapy versus vancomycin lock in a salvation strategy for totally implantable vascular access device infections due to coagulase-negative staphylococci (the ETHALOCK study): a prospective double-blind randomized clinical trial.
Central venous catheter infection
Coagulase-negative staphylococci
Ethanol
Lock solution
Totally implantable vascular access device
Vancomycin
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
23 Nov 2023
23 Nov 2023
Historique:
received:
20
04
2023
accepted:
06
11
2023
medline:
23
11
2023
pubmed:
23
11
2023
entrez:
22
11
2023
Statut:
aheadofprint
Résumé
Little is known about efficacy and safety of ethanol lock therapy (ELT) to treat totally implantable venous access device (TIVAD) infections. The objective of this trial was to evaluate the effectiveness and safety profile of a local treatment with ELT without removal for TIVAD infection due to coagulase-negative staphylococci. We performed a prospective, multicenter, double-blind, randomized clinical trial comparing the efficacy of 40% ELT versus vancomycin lock therapy (VLT) in TIVAD infections due to coagulase-negative staphylococci, complicated or not by bloodstream infection. Thirty-one patients were assigned to the ELT group and 30 to the VLT arm. Concomitant bacteremia was present in 41 patients (67.2%). Treatment success was 58.1 % (18 of 31) for the ELT arm and 46.7% (14 of 30) for the VLT arm (p = 0.37). The overall treatment success was 52.5% (32). The risk of treatment failure due to uncontrolled infections, superinfections, and mechanical complications did not differ significantly between participants receiving ELT (13 out of 31 [42%]) and those receiving VLT (16 out of 30 [53%]) with a hazard ratio of 0.70 (p = 0.343; 95% CI [0.34-1.46], Cox model). Catheter malfunctions were significantly more frequent in the ELT arm (11 patients versus 2 in the VLT group, p = 0.01). We found an overall high rate of treatment failure that did not differ between the ELT arm and the VLT arm. TIVAD removal must be prioritized to prevent complications (uncontrolled infections, superinfections, and catheter malfunctions) except in exceptional situations.
Identifiants
pubmed: 37993679
doi: 10.1007/s10096-023-04702-w
pii: 10.1007/s10096-023-04702-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Walser EM (2012) Venous access ports: indications, implantation technique, follow-up, and complications. Cardiovasc Intervent Radiol 35:751–764. https://doi.org/10.1007/s00270-011-0271-2
doi: 10.1007/s00270-011-0271-2
pubmed: 21922348
Pinelli F, Cecero E, Degl’Innocenti D, Selmi V, Giua R, Villa G, Chelazzi C, Romagnoli S, Pittiruti M (2018) Infection of totally implantable venous access devices: a review of the literature. J Vasc Access 19:230–242. https://doi.org/10.1177/1129729818758999
doi: 10.1177/1129729818758999
pubmed: 29512430
Gapany C, Tercier S, Diezi M, Clement C, Lemay K, Joseph J-M (2011) Frequent accesses to totally implanted vascular ports in pediatric oncology patients are associated with higher infection rates. J Vasc Access 12:207–210. https://doi.org/10.5301/JVA.2011.6258
doi: 10.5301/JVA.2011.6258
pubmed: 21279951
Dibb M, Lal S (2017) Home parenteral nutrition: vascular access and related complications. Nutr Clin Pract 32:769–776. https://doi.org/10.1177/0884533617734788
doi: 10.1177/0884533617734788
pubmed: 29023196
Wang TY, Lee KD, Chen PT, Chen MC, Chen YY, Huang CE, Kuan FC, Chen CC, Lu CH (2015) Incidence and risk factors for central venous access port-related infection in Chinese cancer patients. J Formos Med Assoc 114:1055–1060. https://doi.org/10.1016/j.jfma.2015.06.013
doi: 10.1016/j.jfma.2015.06.013
pubmed: 26253646
Shim J, Seo T-S, Song MG, Cha I-H, Kim JS, Choi CW, Seo JH, Oh SC (2014) Incidence and risk factors of infectious complications related to implantable venous-access ports. Korean J Radiol 15:494–500. https://doi.org/10.3348/kjr.2014.15.4.494
doi: 10.3348/kjr.2014.15.4.494
pubmed: 25053910
pmcid: 4105813
Zerati AE, Figueredo TR, de Moraes RD, da Cruz AM, da Motta-Leal Filho JM, Freire MP, Wolosker N, de Luccia N (2016) Risk factors for infectious and noninfectious complications of totally implantable venous catheters in cancer patients. J Vasc Surg Venous Lymphat Disord 4:200–205. https://doi.org/10.1016/j.jvsv.2015.10.008
doi: 10.1016/j.jvsv.2015.10.008
pubmed: 26993868
Lebeaux D, Fernández-Hidalgo N, Chauhan A, Lee S, Ghigo J-M, Almirante B, Beloin C (2014) Management of infections related to totally implantable venous-access ports: challenges and perspectives. Lancet Infect Dis 14:146–159. https://doi.org/10.1016/S1473-3099(13)70266-4
doi: 10.1016/S1473-3099(13)70266-4
pubmed: 24314751
Laporte-Amargos J, Sastre E, Bergas A, Pomares H, Paviglianiti A, Rodriguez-Arias M, Pallares N, Badia-Tejero AM, Pons-Oltra P, Carratalà J, Gudiol C (2023) Increasing gram-negative catheter-related bloodstream infection in cancer patients. Pathogens 12:228. https://doi.org/10.3390/pathogens12020228
doi: 10.3390/pathogens12020228
pubmed: 36839500
pmcid: 9963750
Flynn PM, Willis B, Gaur AH, Shenep JL (2003) Catheter design influences recurrence of catheter-related bloodstream infection in children with cancer. J Clin Oncol 21:3520–3525. https://doi.org/10.1200/JCO.2003.03.012
doi: 10.1200/JCO.2003.03.012
pubmed: 12972529
Aumeran C, Guyot P, Boisnoir M, Robin-Hennequin C, Vidal M, Forestier C, Traore O, Lesens O, Clermont-Ferrand Biofilm Study Group (2013) Activity of ethanol and daptomycin lock on biofilm generated by an in vitro dynamic model using real subcutaneous injection ports. Eur J Clin Microbiol Infect Dis 32:199–206. https://doi.org/10.1007/s10096-012-1732-5
doi: 10.1007/s10096-012-1732-5
pubmed: 23079900
Morales M, Méndez-Alvarez S, Martín-López J-V, Marrero C, Freytes CO (2004) Biofilm: the microbial “bunker” for intravascular catheter-related infection. Support Care Cancer 12:701–707. https://doi.org/10.1007/s00520-004-0630-5
doi: 10.1007/s00520-004-0630-5
pubmed: 15095074
Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, Raad II, Rijnders BJA, Sherertz RJ, Warren DK (2009) Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 49:1–45. https://doi.org/10.1086/599376
doi: 10.1086/599376
pubmed: 19489710
Rijnders BJ, Van Wijngaerden E, Vandecasteele SJ, Stas M, Peetermans WE (2005) Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. J Antimicrob Chemother 55:90–94. https://doi.org/10.1093/jac/dkh488
doi: 10.1093/jac/dkh488
pubmed: 15574481
Raad I, Hanna H, Dvorak T, Chaiban G, Hachem R (2007) Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm. Antimicrob Agents Chemother 51:78–83. https://doi.org/10.1128/AAC.00154-06
doi: 10.1128/AAC.00154-06
pubmed: 17074799
Chambers ST, Pithie A, Gallagher K, Liu T, Charles CJ, Seaward L (2007) Treatment of Staphylococcus epidermidis central vascular catheter infection with 70% ethanol locks: efficacy in a sheep model. J Antimicrob Chemother 59:779–782. https://doi.org/10.1093/jac/dkl542
doi: 10.1093/jac/dkl542
pubmed: 17283033
Balestrino D, Souweine B, Charbonnel N, Lautrette A, Aumeran C, Traoré O, Forestier C (2009) Eradication of microorganisms embedded in biofilm by an ethanol-based catheter lock solution. Nephrol Dial Transplant 24:3204–3209. https://doi.org/10.1093/ndt/gfp187
doi: 10.1093/ndt/gfp187
pubmed: 19383833
Sofroniadou S, Revela I, Kouloubinis A, Makriniotou I, Zerbala S, Smirloglou D, Kalocheretis P, Drouzas A, Samonis G, Iatrou C (2017) Ethanol combined with heparin as a locking solution for the prevention of catheter related blood stream infections in hemodialysis patients: a prospective randomized study. Hemodial Int 21:498–506. https://doi.org/10.1111/hdi.12524
doi: 10.1111/hdi.12524
pubmed: 28078825
Schoot RA, van Ommen CH, Stijnen T, Tissing WJE, Michiels E, Abbink FCH, Raphael MF, Heij HA, Lieverst JA, Spanjaard L, Zwaan CM, Caron HN, van de Wetering MD (2015) Prevention of central venous catheter-associated bloodstream infections in paediatric oncology patients using 70% ethanol locks: a randomised controlled multi-centre trial. Eur J Cancer 51:2031–2038. https://doi.org/10.1016/j.ejca.2015.06.126
doi: 10.1016/j.ejca.2015.06.126
pubmed: 26188849
Salonen BR, Bonnes SL, Vallumsetla N, Varayil JE, Mundi MS, Hurt RT (2018) A prospective double blind randomized controlled study on the use of ethanol locks in HPN patients. Clin Nutr 37:1181–1185. https://doi.org/10.1016/j.clnu.2017.05.009
doi: 10.1016/j.clnu.2017.05.009
pubmed: 28576557
Souweine B, Lautrette A, Gruson D, Canet E, Klouche K, Argaud L, Bohe J, Garrouste-Orgeas M, Mariat C, Vincent F, Cayot S, Cointault O, Lepape A, Guelon D, Darmon M, Vesin A, Caillot N, Schwebel C, Boyer A et al (2015) Ethanol lock and risk of hemodialysis catheter infection in critically ill patients. A randomized controlled trial. Am J Respir Crit Care Med 191:1024–1032. https://doi.org/10.1164/rccm.201408-1431OC
doi: 10.1164/rccm.201408-1431OC
pubmed: 25668557
Broom JK, Krishnasamy R, Hawley CM, Playford EG, Johnson DW (2012) A randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients--the HEALTHY-CATH trial. BMC Nephrol 13:146. https://doi.org/10.1186/1471-2369-13-146
doi: 10.1186/1471-2369-13-146
pubmed: 23121768
pmcid: 3531247
Pérez-Granda MJ, Barrio JM, Muñoz P, Hortal J, Rincón C, Rabadán PM, Pernia MS, Bouza E (2014) Ethanol lock therapy (E-Lock) in the prevention of catheter-related bloodstream infections (CR-BSI) after major heart surgery (MHS): a randomized clinical trial. PLoS One 9:e91838. https://doi.org/10.1371/journal.pone.0091838
doi: 10.1371/journal.pone.0091838
pubmed: 24675993
pmcid: 3967996
Lopes BC, Borges PSGN, Gallindo RM, Tenório TBS, Machado LB, de Orange FA (2019) Ethanol lock therapy for the prevention of nontunneled catheter-related bloodstream infection in pediatric patients. JPEN J Parenter Enteral Nutr 43:1044–1052. https://doi.org/10.1002/jpen.1508
doi: 10.1002/jpen.1508
pubmed: 30773689
Worth LJ, Slavin MA, Heath S, Szer J, Grigg AP (2014) Ethanol versus heparin locks for the prevention of central venous catheter-associated bloodstream infections: a randomized trial in adult haematology patients with Hickman devices. J Hosp Infect 88:48–51. https://doi.org/10.1016/j.jhin.2014.06.007
doi: 10.1016/j.jhin.2014.06.007
pubmed: 25063013
Slobbe L, Doorduijn JK, Lugtenburg PJ, El Barzouhi A, Boersma E, van Leeuwen WB, Rijnders BJA (2010) Prevention of catheter-related bacteremia with a daily ethanol lock in patients with tunnelled catheters: a randomized, placebo-controlled trial. PLoS One 5:e10840. https://doi.org/10.1371/journal.pone.0010840
doi: 10.1371/journal.pone.0010840
pubmed: 20520776
pmcid: 2877107
Wolf J, Connell TG, Allison KJ, Tang L, Richardson J, Branum K, Borello E, Rubnitz JE, Gaur AH, Hakim H, Su Y, Federico SM, Mechinaud F, Hayden RT, Monagle P, Worth LJ, Curtis N, Flynn PM (2018) Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial. Lancet Infect Dis 18:854–863. https://doi.org/10.1016/S1473-3099(18)30224-X
doi: 10.1016/S1473-3099(18)30224-X
pubmed: 29884572
Khosroshahi HT, Mahdipur H, Parkhideh S, Basmenji S, Khalilzadeh M, Tozihi M (2015) The effectiveness of systemic antibiotic therapy with and without ethanol-locked solution in the treatment of hemodialysis-related catheter infection. Saudi J Kidney Dis Transpl 26:477–481. https://doi.org/10.4103/1319-2442.157315
doi: 10.4103/1319-2442.157315
pubmed: 26022017
Mermel LA, Farr BM, Sherertz RJ, Raad II, O’Grady N, Harris JS, Craven DE, Infectious Diseases Society of America, American College of Critical Care Medicine, Society for Healthcare Epidemiology of America (2001) Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 32:1249–1272. https://doi.org/10.1086/320001
doi: 10.1086/320001
pubmed: 11303260
Kurul S, Saip P, Aydin T (2002) Totally implantable venous-access ports: local problems and extravasation injury. Lancet Oncol 3:684–692. https://doi.org/10.1016/s1470-2045(02)00905-1
doi: 10.1016/s1470-2045(02)00905-1
pubmed: 12424071
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN, REDCap Consortium (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inform 95:103208. https://doi.org/10.1016/j.jbi.2019.103208
doi: 10.1016/j.jbi.2019.103208
pubmed: 31078660
pmcid: 7254481
Wolf J, Shenep JL, Clifford V, Curtis N, Flynn PM (2013) Ethanol lock therapy in pediatric hematology and oncology. Pediatr Blood Cancer 60:18–25. https://doi.org/10.1002/pbc.24249
doi: 10.1002/pbc.24249
pubmed: 22911535
Buonsenso D, Salerno G, Sodero G, Mariani F, Pisapia L, Gelormini C, Di Nardo M, Valentini P, Scoppettuolo G, Biasucci DG (2022) Catheter salvage strategies in children with central venous catheter-related or -associated bloodstream infections: a systematic review and meta-analysis. J Hosp Infect 125:1–20. https://doi.org/10.1016/j.jhin.2022.03.010
doi: 10.1016/j.jhin.2022.03.010
pubmed: 35390396
Mermel LA, Alang N (2014) Adverse effects associated with ethanol catheter lock solutions: a systematic review. J Antimicrob Chemother 69:2611–2619. https://doi.org/10.1093/jac/dku182
doi: 10.1093/jac/dku182
pubmed: 24891431
Guenu S, Heng A-E, Charbonné F, Galmier M-J, Charlès F, Deteix P, Souweine B, Lartigue C (2007) Mass spectrometry and scanning electron microscopy study of silicone tunneled dialysis catheter integrity after an exposure of 15 days to 60% ethanol solution. Rapid Commun Mass Spectrom 21:229–236. https://doi.org/10.1002/rcm.2837
doi: 10.1002/rcm.2837
pubmed: 17171773
Msakni N, Galmier M-J, Couret M-J, Szczepaniak C, Bouchon B, Souweine B, Lartigue C (2013) Complementary mass spectrometric approaches and scanning electron microscopy to study the structural stability of polyurethane tunneled dialysis catheters after exposure to ethanol solutions. Rapid Commun Mass Spectrom 27:2343–2354. https://doi.org/10.1002/rcm.6691
doi: 10.1002/rcm.6691
pubmed: 24097390
Calvet L, Piot M, Lartigue C, Souweine B, Tardy-Poncet B (2015) Anticoagulant properties of enoxaparin 400 IU/mL-40% ethanol catheter lock solution. Springerplus 4:746. https://doi.org/10.1186/s40064-015-1533-2
doi: 10.1186/s40064-015-1533-2
pubmed: 26693105
pmcid: 4666847
Balestrino D, Quintana M, Charbonnel N, Forestier C, Lartigue C, Souweine B (2016) Compatibility of injectable anticoagulant agents in ethanol; in vitro antibiofilm activity and impact on polyurethane catheters of enoxaparin 400 U/mL in 40% v/v ethanol. PLoS One 11:e0159475. https://doi.org/10.1371/journal.pone.0159475
doi: 10.1371/journal.pone.0159475
pubmed: 27441664
pmcid: 4956118
Schilcher G, Schlagenhauf A, Schneditz D, Scharnagl H, Ribitsch W, Krause R, Rosenkranz AR, Stojakovic T, Horina JH (2013) Ethanol causes protein precipitation--new safety issues for catheter locking techniques. PLoS One 8:e84869. https://doi.org/10.1371/journal.pone.0084869